Selank vs Semax: How Two Neuropeptides Compare

Brain Peptide Bioregulators

84 Genes

Selank altered expression of 84 neurotransmission-related genes in rat frontal cortex in a single study, spanning GABA, serotonin, and dopamine systems.

Filatova et al., Frontiers in Pharmacology, 2017

Filatova et al., Frontiers in Pharmacology, 2017

View as image

Selank and Semax are two synthetic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1990s. Both are registered medications in Russia. Both are administered intranasally. And both target the central nervous system. But they do fundamentally different things. Selank is classified as an anxiolytic. Semax is classified as a nootropic. Their parent molecules, receptor targets, and downstream effects diverge sharply, and the research base for each peptide tells a different story. This article is part of the brain peptide bioregulators cluster, which covers Russian-developed neuropeptides and their evidence base.

Where Selank and Semax Come From

Both peptides emerged from the same laboratory, but they were built from entirely different blueprints.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a seven-amino-acid peptide derived from tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the heavy chain of immunoglobulin G.^[1] The Russian team extended tuftsin's C-terminus with Pro-Gly-Pro to improve metabolic stability. Tuftsin itself is an immune modulator, not a neurotransmitter, which is why Selank's immunomodulatory effects were among the first properties documented.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is also seven amino acids, but its core is ACTH(4-10), a fragment of adrenocorticotropic hormone. Like Selank, the C-terminal Pro-Gly-Pro extension prevents rapid enzymatic degradation.^[2] ACTH fragments have long been associated with attention and memory in animal models, which is why Semax was developed as a nootropic rather than an anxiolytic.

The structural difference matters because it determines receptor binding. Selank's tuftsin backbone gives it affinity for systems involved in immune regulation and, unexpectedly, GABAergic signaling. Semax's ACTH backbone gives it access to melanocortin-adjacent pathways and neurotrophin regulation.

How Selank Works: GABA, Enkephalins, and Anxiety

Selank's primary mechanism centers on the GABAergic system. A 2017 study by Filatova et al. examined the expression of genes involved in GABAergic neurotransmission in human neuroblastoma cells (IMR-32) after Selank exposure. The peptide altered expression of genes encoding GABA-A receptor subunits, GABA transporters, and glutamic acid decarboxylase, the enzyme that synthesizes GABA.^[3] The pattern resembled benzodiazepine-like modulation, but without direct receptor binding.

The enkephalin pathway adds a second layer. Zozulya et al. (2001) measured enkephalin-degrading enzyme activity in blood samples from 62 patients with generalized anxiety disorder and found that anxiety patients had accelerated enkephalin breakdown. Selank's anxiolytic effect correlated with its ability to inhibit these enzymes, preserving endogenous opioid-mediated anxiety relief.^[1] The effect was comparable to medazepam in clinical assessment scales (Hamilton, Zung, CGI) but carried additional antiasthenic and psychostimulant properties that the benzodiazepine lacked.

In a 2017 animal study, Kasian et al. showed that Selank enhanced the anxiolytic effect of diazepam in rats subjected to unpredictable chronic mild stress. The combination produced greater anxiety reduction than either compound alone, suggesting Selank works through complementary rather than identical pathways to classical benzodiazepines.^[4]

Selank also acts on serotonin and other neurotransmitter systems, which likely explains its broader spectrum compared to pure GABAergic drugs.

How Semax Works: BDNF, Dopamine, and Neurotrophin Cascades

Semax's signature effect is BDNF upregulation. Dolotov et al. (2003) administered Semax intranasally to rats and measured BDNF mRNA in multiple brain regions. Within 30 minutes, BDNF expression in the hippocampus increased roughly 50-fold. The effect was region-specific: basal forebrain and frontal cortex showed significant increases, while the hypothalamus did not respond.^[5]

A follow-up study from the same group (Dolotov et al., 2006) confirmed that Semax not only increased BDNF mRNA but also raised BDNF protein levels and upregulated trkB, the receptor through which BDNF signals.^[6] This is a critical distinction. Many compounds can transiently boost mRNA without producing functional protein. Semax appeared to do both, at least in rat hippocampus.

The dopamine and serotonin effects operate independently from the BDNF pathway. Eremin et al. (2005) measured monoamine metabolites in six brain regions of rats after Semax injection. HVA (a dopamine metabolite) increased by approximately 80% in the striatum, while 5-HIAA (a serotonin metabolite) rose by about 30% in the same region.^[7] This dual monoaminergic activation likely underlies Semax's effects on attention and motivation.

Semax has also been studied as a neuroprotective agent. Romanova et al. (2006) tested Semax in rats with experimental ischemic infarction of the cerebral cortex and found both neuroprotective and antiamnesic effects: treated animals showed less tissue damage and better retention of learned behaviors compared to controls.^[8] These neuroprotective properties connect to the broader field of neurotrophic peptides and brain health.

Head-to-Head: Where the Evidence Diverges

The comparison reveals a pattern: Selank is primarily anxiolytic with secondary cognitive effects, while Semax is primarily cognitive-enhancing with secondary mood effects. A 2024 study by Inozemtseva et al. tested Semax specifically for antidepressant and antistress properties in chronically stressed rats and found significant effects, but the mechanism involved dopaminergic and serotonergic activation rather than GABAergic modulation.^[9] Semax can reduce stress, but it gets there through a fundamentally different route than Selank.

Brain Network Evidence: The Connectomic Study

One study directly compared both peptides in the same experimental framework. Panikratova et al. (2020) used functional connectivity analysis to examine how Selank and Semax altered brain network activity in healthy volunteers. The study found that each peptide activated distinct neural circuits, with only partial overlap.^[10]

This is the closest thing to a direct head-to-head comparison in the literature. The results align with the pharmacological differences: Selank shifted activity in circuits associated with emotional regulation, while Semax shifted activity in circuits associated with attention and executive function. The partial overlap is consistent with both peptides affecting serotonergic signaling, just from different angles.

For context on how other peptides compare in cognitive enhancement, see the nootropic peptides overview and the Noopept profile.

Beyond Anxiety and Cognition: Other Research Directions

Both peptides show up in research areas beyond their primary classifications.

Alcohol-related research. Selank has been studied in ethanol models from multiple angles. Kolik et al. (2019) found that Selank protected against ethanol-induced memory impairment in rats by regulating BDNF content in the hippocampus and prefrontal cortex.^[11] The BDNF connection is notable because it means Selank, typically characterized as a GABA modulator, can also influence neurotrophin pathways under certain conditions.

Neurodegeneration. Slominsky et al. (2017) tested both peptides in rats with 6-OHDA-induced Parkinson's-like symptoms. Both Semax and Selank improved behavioral outcomes, but gene expression analysis revealed different protective mechanisms: Semax upregulated neurotrophic factors while Selank modulated stress-response genes.^[12]

Immune modulation. Leonidovna et al. (2021) examined Selank's effect on cytokine levels under social stress conditions and found that Selank normalized stress-altered cytokine profiles, connecting its anxiolytic effects to immune regulation.^[13] Semax shows immune effects too, but primarily in the context of ischemic brain injury, where it upregulates chemokine and immunoglobulin genes as part of a broader neuroprotective response.

Limitations of the Current Evidence

The research base for both peptides shares several weaknesses worth noting.

Most studies come from Russian laboratories, many published in Russian-language journals with limited English-language peer review. This does not invalidate the science, but it does limit independent replication. The standard practice in Western drug development, where competing labs attempt to reproduce key findings before clinical adoption, has not been widely applied to either peptide. Few if any Western academic groups have published independent confirmation of the core mechanistic claims.

Human clinical data is thin. Selank's strongest human evidence comes from a single 62-patient anxiety trial from 2001 that compared it to only one benzodiazepine. Semax's clinical data comes primarily from Russian stroke studies conducted over two decades ago. Neither peptide has undergone the kind of large, multi-center, placebo-controlled trials that regulatory agencies in Europe or North America require for drug approval. Phase III trial data, the gold standard, does not exist for either compound in Western regulatory frameworks.

The animal studies, while internally consistent within individual research groups, use diverse models and dosing protocols that make cross-study comparison difficult. BDNF fold-changes, for instance, vary dramatically depending on the brain region sampled, the time point measured, the route of administration, and the strain of rat used. A 50-fold mRNA increase in one study does not necessarily translate to the same magnitude of protein-level change or functional outcome in a different experimental setup.

Dose-response data in humans is sparse. The optimal intranasal doses for cognitive or anxiolytic effects have not been established through systematic dose-ranging trials. Most human use outside of Russian clinical settings is based on extrapolation from animal data or anecdotal reports.

Neither Selank nor Semax is approved by the FDA, EMA, or most regulatory agencies outside of Russia and a few CIS countries. Both are available through research chemical suppliers, but quality control, purity verification, and peptide identity confirmation in this market are inconsistent.

Who Studies What, and Why

The division between these two peptides maps to different clinical needs. Selank research clusters around anxiety, stress resilience, and conditions where emotional regulation is impaired. Semax research clusters around cognitive decline, neurodegeneration, and conditions where BDNF or neurotrophin deficiency plays a role.

This specialization reflects their origins. Tuftsin, Selank's parent, is an immune peptide that was repurposed for neuroscience. ACTH, Semax's parent, is a stress hormone fragment that was optimized for cognition. Each peptide inherited the biological neighborhood of its ancestor.

The two peptides are not competitors. They target different aspects of brain function through different mechanisms, and the limited evidence available suggests they may be complementary rather than redundant. Whether that complementarity translates into clinical benefit for any specific condition remains an open question, one that can only be resolved by trials designed to test it.

For comparison with other peptide-derived cognitive enhancers, see the profile on Dihexa, a peptide described as millions of times more potent than BDNF.

The Bottom Line

Selank and Semax are both seven-amino-acid peptides from the same Russian laboratory, but they diverge at every mechanistic level. Selank modulates GABA, enkephalins, and immune cytokines, producing anxiolytic effects comparable to benzodiazepines without their side effects in one 62-patient trial. Semax upregulates BDNF up to 50-fold, activates dopamine and serotonin pathways, and shows neuroprotective effects in ischemia models. Human data for both peptides remains limited and largely confined to Russian clinical settings.

Frequently Asked Questions

What is the difference between Selank and Semax?

Selank is a tuftsin-derived peptide that primarily modulates GABA receptors and enkephalin-degrading enzymes, producing anxiolytic (anti-anxiety) effects. Semax is an ACTH(4-10) analog that primarily upregulates BDNF and activates dopamine and serotonin systems, producing nootropic (cognitive-enhancing) effects. A 2020 functional connectomic study confirmed they activate distinct brain networks in human subjects (Panikratova et al., 2020).

Can you take Selank and Semax together?

Some researchers have studied both peptides in the same experimental framework. Panikratova et al. (2020) found that Selank and Semax activate partially overlapping but distinct brain circuits. In the 6-OHDA Parkinson's model, both showed protective effects through different mechanisms (Slominsky et al., 2017). No published studies have specifically evaluated the safety or efficacy of combined administration in humans.

Is Selank a benzodiazepine?

No. Selank is a synthetic peptide, not a benzodiazepine. However, it produces similar anxiolytic effects by modulating GABAergic gene expression (Filatova et al., 2017). In a 62-patient trial, Selank matched medazepam (a benzodiazepine) for anxiety reduction but did not produce the amnesia, sedation, or withdrawal that characterize benzodiazepine use (Zozulya et al., 2001).

Does Semax increase BDNF?

Yes. Dolotov et al. (2003) measured a roughly 50-fold increase in BDNF mRNA in rat hippocampus within 30 minutes of intranasal Semax administration. A follow-up study (Dolotov et al., 2006) confirmed that both BDNF protein levels and trkB receptor expression increased, suggesting functional neurotrophin signaling rather than just transient mRNA changes.

Are Selank and Semax FDA approved?

Neither Selank nor Semax is approved by the FDA, EMA, or most regulatory agencies outside of Russia and certain CIS countries. Both are registered medications in Russia, where Selank is classified as an anxiolytic and Semax as a nootropic. They are available through research suppliers internationally, but quality and purity vary by source.

What are the side effects of Selank and Semax?

Published studies report minimal side effects for both peptides. In the Selank anxiety trial (62 patients), Selank did not produce the amnesia, sedation, or dependence associated with benzodiazepines (Zozulya et al., 2001). Semax studies in stroke patients reported no significant adverse events. However, the total number of human subjects studied is small, and long-term safety data is lacking for both compounds.